Current available maintenance pharmacotherapy for bipolar disorder (BD) leaves ample room for improvement. Up to 50% of patients with BD do not respond adequately to available treatments and still suffer from manic and/or depressive episodes. Although a number of pharmaceutical companies have invested in novel medications, none of the recently developed compounds has shown efficacy for recurrence prevention.
| BACKG ROU N D
Current available maintenance pharmacotherapy for bipolar disorder (BD) leaves ample room for improvement. Up to 50% of patients with BD do not respond adequately to available treatments and still suffer from manic and/or depressive episodes. Although a number of pharmaceutical companies have invested in novel medications, none of the recently developed compounds has shown efficacy for recurrence prevention.
Given that BD is associated with dysregulations of the immune system, there is increasing interest in the therapeutic potential of immune-modulating medications. Although aspirin (acetylsalicylic acid) has been investigated to treat depressive symptoms, 1 low-dose (typically ≤150 mg/day) aspirin may be a particularly promising candidate for recurrence prevention: it is well tolerated, even with longterm use, well absorbed, passes the blood-brain barrier, and likely exerts anti-inflammatory effects in both the brain and the periphery.
In this perspective article, we will give an overview of the neuropharmacodynamics of (low-dose) aspirin, reflect on the published clinical studies and argue that aspirin is a promising, yet understudied option for recurrence prevention.
| PATHOPHYS IOLOG IC AL MECHANIS MS
Aspirin can exert its effect on the neuroimmune system in BD via two pathways: modification of the cyclooxygenase enzymes (COX enzymes) and by stimulation of myelinization. Aspirin is unique among the NSAIDs in that it covalently modifies COX-1 and COX-2
where it has differential effects. 2 Aspirin treatment of COX-1 irreversibly inhibits the cyclooxygenase activity of the enzyme and subsequently the production of prostaglandin G2 (PGG2), blocking the conversion of arachidonic acid (AA) to prostaglandins and thromboxane A2. In the brain, COX-1 is predominantly expressed by microglia, known to be activated in BD. Preclinical evidence suggests that inhibition of COX-1 is neuroprotective after intracerebroventricular administration of lipopolysaccharide (LPS). 2 In contrast to full inhibition of COX-2 by selective COX-2 inhibitors, which is thought to have detrimental effects by increasing leukocyte recruitment into the brain and exacerbating tissue damage, DEBATE tracts. 3 Results from anatomical magnetic resonance imaging (MRI) and more recent whole-brain diffusion tensor imaging (DTI) studies suggest widespread white matter abnormalities in BD, associated with mood episodes and cognitive functioning. A DTI study that we performed demonstrated myelination aberrations in lithium-using patients with BD compared to non-lithium-using patients in large white matter fibers, comparable to observations made in another DTI study by Benedetti et al. Based on these observations, it has been suggested that lithium may have a counteracting effect on white matter microstructural disturbances, possibly being one of its therapeutic mechanisms, via a known inhibition of glycogen synthase kinase 3 beta (GSK-3β). Interestingly, low-dose aspirin was also found to have a stimulating effect on myelin-forming oligodendrocytes in mice, 3 potentially enhancing the effect of lithium via this route. In oncological research, aspirin is known to have an inhibitory effect on GSK-3β as well.
| CLINIC ALLY UNDER S TUDIED
Aspirin has been investigated in only three published clinical studies on treatment of mood and medication side effects in BD. There were no severe adverse events related to aspirin in any of these studies. Of particular importance in BD, low-dose aspirin does not increase serum lithium, contrary to other NSAIDs.
| D ISCUSS I ON
The study by Savitz et al points toward an ameliorating effect of aspirin on depressive symptoms in BD. Since the pathophysiological action of immune modulators primarily focuses on improving the stability of the underlying dysregulated immune and glial cells, they may be even more effective in preventing recurrences.
It is interesting that this hypothetical recurrence-preventing mode of action of low-dose aspirin is supported by the pharmacoepidemiological study by Stolk et al. In this study, low-dose aspirin was found to have a statistically significant duration-independent reduction in the relative risk of clinical deterioration, when compared to subjects not using aspirin. 4 Indeed, studies that investi- well tolerated, has other beneficial health effects, is affordable, and therefore would have a strong favorable cost/benefit ratio, emphasizing the importance of public funding for such trials.
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